p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer - Wikidata - wikimedia - TriplyDB

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer

http://www.wikidata.org/entity/Q37725293

about

Mitogen-activated protein kinase signaling pathway and invasion and metastasis of gastric cancer Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond LACTB is a tumour suppressor that modulates lipid metabolism and cell state.Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression.Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma The landscape of BRAF transcript and protein variants in human cancer.Combined MEK and Pi3'-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo.Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71.MicroRNA Deregulation in Anaplastic Thyroid Cancer Biology.Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.Development and characterization of six new human papillary thyroid carcinoma cell lines.Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.Modulation of sodium iodide symporter in thyroid cancer Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.Mouse models of thyroid cancer: A 2015 update.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.Long noncoding RNA are aberrantly expressed in human papillary thyroid carcinoma Downregulation of Notch-regulated Ankyrin Repeat Protein Exerts Antitumor Activities against Growth of Thyroid Cancer.Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma Modeling anaplastic thyroid carcinoma in the mouse.Overview of Genetically Engineered Mouse Models of Papillary and Anaplastic Thyroid Cancers: Enabling Translational Biology for Patient Care Improvement.NAIF1 inhibits gastric cancer cells migration and invasion via the MAPK pathways.Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors.Structural alterations in tumor-draining lymph nodes before papillary thyroid carcinoma metastasis.Targeted next-generation sequencing of cancer genes in poorly differentiated thyroid cancer.Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.Prognostic value of long non-coding RNA BLACAT1 in patients with papillary thyroid carcinoma.TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation.Management of recurrent or metastatic thyroid cancer.Loss of One or Two PATZ1 Alleles Has a Critical Role in the Progression of Thyroid Carcinomas Induced by the RET/PTC1 Oncogene.Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion Mouse models of sporadic thyroid cancer derived from BRAFV600E alone or in combination with PTEN haploinsufficiency under physiologic TSH levels

P2860

Q26778022-9EAF1299-E280-4EDA-A200-6A39D17D3B6F Q27026323-030F885C-F55D-4044-98E6-211B05C663E8 Q29871523-F1374CDA-96F5-4A8E-A9A3-D4A0133B5E54 Q33558907-A7830E23-D6A6-45D6-9E1B-DA9AEEFE398F Q33591794-A2122CA3-2D5D-4A96-9363-A769DAE16EAE Q33617734-F3F9C858-62CD-4C21-BE7D-1FF752E2C8CC Q33648582-D08286C5-C0C7-4780-A5D5-9F9B0E5BA431 Q33914771-B7C17754-0B22-446F-A8F2-3DDE5A144431 Q34119098-CAC25908-5330-4A7F-8B40-A4A22EBD0BBD Q34123525-994DE0BF-D616-472A-ADC5-1D85F773CB94 Q35055107-DBDBE8BC-A302-43AA-AF98-E2C0C5856251 Q35234108-9FE231F7-E1D0-4807-AA64-B2D887A753E4 Q35690173-88C9390D-A488-4D75-99F6-380FCBB48C75 Q36255616-03829E3C-C4A9-485F-BE70-69BAF10917FC Q36405539-B6EFB020-4C2A-4208-9974-E2D7E04854B9 Q36618604-B1B251D2-E64C-4E0B-917A-2B383A8A4C7F Q37001189-39C04952-F758-4327-883F-B96CAE8AFF0C Q37061023-CD06C407-476E-425A-BB84-8B2BE832BFA2 Q37086237-7C53DCDE-38BC-4DC5-A74C-27A61A527320 Q37376300-1DB59B4C-EE7A-46B7-B459-999866F2E19F Q37712700-62CE20A1-091D-4025-95D2-0974B2318801 Q38270915-BC5B9D41-9457-4DAD-AC36-519112EFA3A5 Q38581928-BF2968B4-1FE2-4B53-A85E-BD81EC673ED5 Q38937130-927B63A2-901C-4200-ACEE-1C7AD310EA56 Q39244943-3005FB85-60C7-49A0-BCE3-AFC51C57FF7D Q39328851-DC1F5515-A694-4413-BF02-FD8625129E6B Q42014310-2A9505EA-F42C-4B7E-AFBD-2129944981A8 Q46636066-A83DE24A-9272-4060-B2D8-EE29F4A040D3 Q47142625-0B4552C4-8C9A-4E36-82EB-F81946D47F6B Q47149651-D4171F4B-C0F6-45B8-96FA-48467D142E4C Q47150624-6BCFB24B-DB47-47F2-8225-031F6ADFC28E Q48088782-76F969B1-2BFF-457C-AECC-91246CC11408 Q52620642-595D485C-45FA-4B2E-B5F9-03931B2D659D Q52664598-0CA8660F-4B3F-4D55-90DA-5A821BC9CAC6 Q52839686-9A27068D-D1D7-4824-B2DE-A11CCA01F0C5 Q53082217-3C514D46-9CE8-4F0A-A3B6-10228C00F8EB Q54979977-E574C8EC-0D48-4363-B11E-9390B84695E7 Q55345025-A04128BA-F0E2-4121-BCD2-7EC31E53090B Q58701147-EDC4EC2B-B347-404F-9D72-F1E35B29993D Q58797975-40B05C67-29E6-441C-9489-2B4630B26170

P2860

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer

http://www.wikidata.org/entity/Q37725293

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 April 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

p53 constrains progression to ...... el of papillary thyroid cancer

@en

p53 constrains progression to ...... l of papillary thyroid cancer.

@nl

type

label

p53 constrains progression to ...... el of papillary thyroid cancer

@en

p53 constrains progression to ...... l of papillary thyroid cancer.

@nl

prefLabel

p53 constrains progression to ...... el of papillary thyroid cancer

@en

p53 constrains progression to ...... l of papillary thyroid cancer.

@nl

P1433

Q37725293-2711E2F5-4CAB-42F6-9824-DFA3817444CA

P1476

Q37725293-51039621-2A83-462A-93D4-5976E7E41439

P2093

Q37725293-5AB1DDAF-7340-4C54-A59E-952BE17938D9

Q37725293-792E5E01-43CE-4FF8-8430-74B045C2AE16

Q37725293-80A2DF42-EF38-4235-9F75-A4454D60FBC0

Q37725293-C57DA404-3184-4A6E-9154-E07D747F6132

Q37725293-CC4AEE14-1BEE-4BC5-B88C-77AC0CC899AF

Q37725293-E63C3639-2F01-4207-AD1E-DC65BD66F883

Q37725293-FD89DE72-CCD6-49D7-A385-4706A878385E

Q37725293-FEE824BF-84DC-4425-A4B0-56162B48E910

P2860

Q37725293-1CEB6792-3A35-4A2B-846D-ABE7C327FCAC

Q37725293-263A6459-FAEA-4841-9901-8F6333DADF41

Q37725293-2E5DCDF0-3E1B-4656-80DE-41122F51A8B4

Q37725293-3153C65C-E180-44F9-8010-A849BE3F9457

Q37725293-341CFCE5-18DA-4437-B3B8-EDBF2983368D

Q37725293-37A82DE2-692D-4881-B344-E9A1F9FD739A

Q37725293-3D5B9AC5-5CF8-4BD1-AACA-CC8160DA82E8

Q37725293-42D4D7E3-CD16-47E6-845A-B7C973F3625E

Q37725293-49CAAE50-01C4-4574-B88B-62C0D14B360D

Q37725293-4BF5C235-5172-41AF-ACD7-3665030DEA2D

P304

Q37725293-71B19A5E-E3DB-4FAE-9628-EDDBD51F6A9C

P31

Q37725293-FFF85207-6836-4BFD-A3C4-1EB240AA7C68

P356

Q37725293-6838A686-E9EE-45DF-9533-F1FB37FCF163

P407

Q37725293-470337E8-47B6-4AC4-816D-578010791AEB

P433

Q37725293-D26AA7A7-2A3B-469C-A279-63E8EFA89020

P478

Q37725293-9C45C356-A859-4D23-83C3-D365B61997D1

P50

Q37725293-8AAC95F1-5DF5-457E-937E-FA130A67B989

P577

Q37725293-A72825DA-E4D4-4349-ACCE-00118C6E21BA

P5875

Q37725293-9C4DF024-6FE8-4159-9235-B3A1AE0BDE07

P698

Q37725293-54D26878-9423-4A6D-9743-CFFF75EFDDD2

P932

Q37725293-FFEB66F6-D86D-4BC8-837A-049C323956BA

P356

PNAS.1404357111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

p53 constrains progression to ...... el of papillary thyroid cancer

@en

P2093

Amanda Vernon

http://www.w3.org/2001/XMLSchema#string

Arjun Bhutkar

http://www.w3.org/2001/XMLSchema#string

David G McFadden

http://www.w3.org/2001/XMLSchema#string

Denise M Crowley

http://www.w3.org/2001/XMLSchema#string

Martin McMahon

http://www.w3.org/2001/XMLSchema#string

Philip M Santiago

http://www.w3.org/2001/XMLSchema#string

Raul Martinez-McFaline

http://www.w3.org/2001/XMLSchema#string

Tyler Jacks

http://www.w3.org/2001/XMLSchema#string

P2860

Bioconductor: open software development for computational biology and bioinformatics

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Targeting the PI3K signaling pathway in cancer

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.

The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma.

Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.

P304

E1600-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1404357111

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261445195

http://www.w3.org/2001/XMLSchema#string

P698

24711431

http://www.w3.org/2001/XMLSchema#string

P932

4000830

http://www.w3.org/2001/XMLSchema#string